Posaconazole
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Fungal Infection
Conditions
Fungal Infection, Acute Myelogenous Leukemia, Neutropenia
Trial Timeline
Dec 1, 2007 → Apr 1, 2009
NCT ID
NCT00686543About Posaconazole
Posaconazole is a approved stage product being developed by Merck for Fungal Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT00686543. Target conditions include Fungal Infection, Acute Myelogenous Leukemia, Neutropenia.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00686621 | Pre-clinical | Completed |
| NCT05065658 | Pre-clinical | Completed |
| NCT03318159 | Phase 2 | Completed |
| NCT03336502 | Phase 1 | Completed |
| NCT02387983 | Phase 1 | Completed |
| NCT02020213 | Approved | Withdrawn |
| NCT00811642 | Phase 3 | Completed |
| NCT00686543 | Approved | Completed |
| NCT00550732 | Phase 2 | Completed |
| NCT00726609 | Pre-clinical | Completed |
| NCT00034658 | Phase 3 | Completed |
Competing Products
20 competing products in Fungal Infection